Common use of Formulations Clause in Contracts

Formulations. The clinical dosage form for KPT-8602 is an [**] for oral administration. Initial supplies came in two strengths of active ingredient: 5 mg and 20 mg of the active pharmaceutical ingredient per tablet. Additional supplies for the clinic included the addition of a 10 mg tablet based on the 5 mg formulation and are size proportional (2x) to the 5 mg tablet. All inactive ingredients used in the tablets are either compendia or generally recognized as safe. Tablets are film coated for ease in handling.

Appears in 2 contracts

Sources: License Agreement (Karyopharm Therapeutics Inc.), License Agreement (Karyopharm Therapeutics Inc.)